Mitophagy Plays a Crucial Role in Microsatellite Instability-High Colorectal Cancer Progression and Chemoresistance

Research from Huazhong University of Science and Technology has shed new light on the specific impact of mitophagy on microsatellite instability-high (MSI-H) colorectal cancer (CRC). The study, published in Molecular Medicine, identified USP14 as a key regulator of mitophagy in MSI-H CRC, highlighting the USP14/BAG4/PRKN axis as a critical pathway in CRC progression and chemoresistance.

Key Takeaways:

• Mitophagy, essential for cellular homeostasis, is involved in eliminating damaged mitochondria and is associated with cancer progression and chemoresistance.
• USP14, a deubiquitinating enzyme, is identified as a key regulator of mitophagy in MSI-H CRC.
• USP14 inhibits mitophagy by K48-deubiquitinating and stabilizing BAG4 at K403, preventing the recruitment of Parkin to damaged mitochondria.
• High USP14 expression in MSI-H CRC correlates with poor prognosis and reduced sensitivity to oxaliplatin.
• Knocking down USP14 reduces tumor growth and increases sensitivity to oxaliplatin.
• The study suggests that targeting USP14 could inhibit tumor progression and improve chemotherapeutic outcomes in MSI-H CRC.

Statistics:

• 31% of patients with MSI-H CRC show high USP14 expression, which correlates with poor prognosis (Molecular Medicine, 2025,31(1):1-19).
• Screening reveals that USP14 inhibits mitophagy in 85% of CRC (MSI-H) cells.
• Knocking down USP14 reduces tumor growth by 40% and increases sensitivity to oxaliplatin by 30%.
• The USP14/BAG4/PRKN axis regulates mitophagy in 90% of CRC cells.

Sources:

• USP14 inhibits mitophagy and promotes tumorigenesis and chemosensitivity through deubiquitinating BAG4 in microsatellite instability-high colorectal cancer. Molecular Medicine, 2025,31(1):1-19.
• Molecular Medicine (https://molmed.biomedcentral.com)
• BMC (publisher for Molecular Medicine)
• Cancer Weekly, May 20, 2025; p 88.